Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Eyepoint Inc's Business Segments
Eyepoint Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 1
Regions Reported
-
Eyepoint Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product67.1%
- Royalty20.3%
- License and Collaboration Agreement12.6%
- Royalty Purchase Agreement0%
- Product Rights Agreement0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 0 | 67.1% |
| Royalty | $ 0 | 20.3% |
| License and Collaboration Agreement | $ 0 | 12.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
2 more categories available
Sign in to unlock the full Eyepoint Inc dataset.
Description of Eyepoint Inc
Eyepoint Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of innovative therapeutics for eye diseases. It is based in Watertown, Massachusetts and was established in 198 The company's primary goal is to improve the lives of patients who suffer from serious ophthalmic conditions.
Eyepoint Pharmaceuticals specializes in the development of sustained-release drug delivery systems, which provide a continuous release of medication over an extended period of time. This approach allows for better patient compliance and reduces the number of required injections or surgeries.
The company's flagship product is DEXYCU (dexamethasone intraocular suspension), a novel sustained-release intracameral steroid indicated for the treatment of postoperative inflammation following cataract surgery. DEXYCU is administered as a single dose at the end of surgery, eliminating the need for additional postoperative drops.
Another key product in Eyepoint's pipeline is YUTIQ (fluocinolone acetonide intravitreal implant), a non-biodegradable intravitreal implant for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ is designed to provide up to 36 months of continuous drug release, reducing the burden of frequent intravitreal injections.
Eyepoint Pharmaceuticals has also developed a proprietary delivery technology known as Verisome, which enables the sustained release of therapeutic agents. This platform technology can potentially be applied to a wide range of ophthalmic drugs, expanding the company's product pipeline.
In addition to its proprietary products, Eyepoint Pharmaceuticals has strategic collaborations and licensing agreements with other pharmaceutical companies to further enhance its expertise and expand its portfolio. These collaborations focus on the development of novel ocular therapies, including treatments for retinal diseases, dry eye syndrome, and glaucoma.
The company is committed to advancing ophthalmic research and development, with a team of experienced scientists, clinicians, and industry professionals. Their research efforts encompass preclinical studies, clinical trials, and ongoing post-marketing studies to evaluate the safety and effectiveness of their products.
Eyepoint Pharmaceuticals has a strong commitment to patient care and works closely with healthcare professionals to provide training and support on the use of their products. They also collaborate with patient advocacy groups to raise awareness about eye diseases and improve access to innovative treatments.
In terms of regulatory milestones, Eyepoint Pharmaceuticals has gained approval from the U.S. Food and Drug Administration (FDA) for several of their products. The company continues to pursue approvals in other regions around the world.
Overall, Eyepoint Pharmaceuticals Inc is a leading biopharmaceutical company in the ophthalmic field, dedicated to developing innovative sustained-release therapeutics to improve patient outcomes and quality of life. Through their extensive research, collaborations, and commitment to advancing ocular care, they continue to make significant contributions to the field of ophthalmology.
Eyepoint Pharmaceuticals specializes in the development of sustained-release drug delivery systems, which provide a continuous release of medication over an extended period of time. This approach allows for better patient compliance and reduces the number of required injections or surgeries.
The company's flagship product is DEXYCU (dexamethasone intraocular suspension), a novel sustained-release intracameral steroid indicated for the treatment of postoperative inflammation following cataract surgery. DEXYCU is administered as a single dose at the end of surgery, eliminating the need for additional postoperative drops.
Another key product in Eyepoint's pipeline is YUTIQ (fluocinolone acetonide intravitreal implant), a non-biodegradable intravitreal implant for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ is designed to provide up to 36 months of continuous drug release, reducing the burden of frequent intravitreal injections.
Eyepoint Pharmaceuticals has also developed a proprietary delivery technology known as Verisome, which enables the sustained release of therapeutic agents. This platform technology can potentially be applied to a wide range of ophthalmic drugs, expanding the company's product pipeline.
In addition to its proprietary products, Eyepoint Pharmaceuticals has strategic collaborations and licensing agreements with other pharmaceutical companies to further enhance its expertise and expand its portfolio. These collaborations focus on the development of novel ocular therapies, including treatments for retinal diseases, dry eye syndrome, and glaucoma.
The company is committed to advancing ophthalmic research and development, with a team of experienced scientists, clinicians, and industry professionals. Their research efforts encompass preclinical studies, clinical trials, and ongoing post-marketing studies to evaluate the safety and effectiveness of their products.
Eyepoint Pharmaceuticals has a strong commitment to patient care and works closely with healthcare professionals to provide training and support on the use of their products. They also collaborate with patient advocacy groups to raise awareness about eye diseases and improve access to innovative treatments.
In terms of regulatory milestones, Eyepoint Pharmaceuticals has gained approval from the U.S. Food and Drug Administration (FDA) for several of their products. The company continues to pursue approvals in other regions around the world.
Overall, Eyepoint Pharmaceuticals Inc is a leading biopharmaceutical company in the ophthalmic field, dedicated to developing innovative sustained-release therapeutics to improve patient outcomes and quality of life. Through their extensive research, collaborations, and commitment to advancing ocular care, they continue to make significant contributions to the field of ophthalmology.
Eyepoint Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of eye diseases. The company leverages its proprietary drug delivery technology to create sustained-release formulations that address significant unmet needs in the ophthalmic market. Below is an extensive description of the segments, products, and services offered by Eyepoint Pharmaceuticals.
Segments
1. Ocular Drug Delivery Technology:
Eyepoint Pharmaceuticals has invested heavily in developing its proprietary technologies aimed at delivering medications directly to the eye. The significant technologies include:
- Durasert™ Technology: This platform uses an innovative polymer matrix to release drugs over an extended period. It minimizes the need for frequent dosages, providing a more effective treatment regimen for patients.
- Yutiq® Technology: A specific application of Durasert, designed primarily for the sustained release of medication to address chronic eye conditions.
2. Product Development:
The company focuses on the internal development of therapies for various ophthalmic conditions, which include but are not limited to:
- Diabetic Macular Edema (DME): A serious eye condition that can lead to vision impairment and blindness, DME is a primary focus of Eyepoint’s efforts in drug development.
- Uveitis: An inflammatory condition affecting the middle layer of the eye, which can result in vision loss if not adequately treated.
Products
1. Yutiq®:
- Overview: Yutiq (fluocinolone acetonide intravitreal implant) is a sustained-release corticosteroid implant approved for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
- Administration: Administered via an in-office procedure, Yutiq provides sustained drug delivery for up to three years, potentially reducing the need for frequent injections and improving patient compliance.
2. DEXYCU®:
- Overview: DEXYCU (dexamethasone intraocular suspension) is a biodegradable drug delivery system designed to treat post-operative inflammation following cataract surgery.
- Benefit: Unlike conventional steroid treatments that require multiple doses, DEXYCU provides a single-dose, sustained-release option that helps manage inflammation effectively and reduces patient burden.
3. Integrated Drug Delivery Systems:
Eyepoint is engaged in developing additional product candidates utilizing its Durasert technology. This encompasses programs aimed at treating various retinal diseases and conditions that require long-term therapy.
Services
1. Clinical Development:
Eyepoint Pharmaceuticals engages in extensive clinical trials to evaluate the safety and efficacy of its product candidates. The company conducts both early-stage and late-stage clinical trials, often working with leading research institutions and ophthalmology experts.
2. Regulatory Support:
The company provides comprehensive support to navigate the complexities of regulatory approvals required for its products. This service involves preclinical assessments, IND applications, and the management of clinical study applications with relevant regulatory bodies.
3. Commercialization Strategies:
Eyepoint focuses on developing strategic partnerships for the commercialization of its products. This includes collaborations with larger pharmaceutical companies that have extensive distribution networks as well as the execution of marketing strategies to increase product awareness and uptake.
4. Educational Programs:
The company also engages in educational initiatives aimed at healthcare professionals and patients. These programs focus on raising awareness about eye diseases, the importance of treatment adherence, and the innovative solutions offered by Eyepoint’s products.
Conclusion
Eyepoint Pharmaceuticals Inc. stands at the forefront of innovation in ocular therapeutics, particularly with its advanced drug delivery technologies and commitment to addressing unmet needs in eye care. With its focus on long-lasting, patient-friendly treatment options, the company seeks to make significant strides in the management of chronic eye diseases, ultimately enhancing the quality of life for those affected.
Segments
1. Ocular Drug Delivery Technology:
Eyepoint Pharmaceuticals has invested heavily in developing its proprietary technologies aimed at delivering medications directly to the eye. The significant technologies include:
- Durasert™ Technology: This platform uses an innovative polymer matrix to release drugs over an extended period. It minimizes the need for frequent dosages, providing a more effective treatment regimen for patients.
- Yutiq® Technology: A specific application of Durasert, designed primarily for the sustained release of medication to address chronic eye conditions.
2. Product Development:
The company focuses on the internal development of therapies for various ophthalmic conditions, which include but are not limited to:
- Diabetic Macular Edema (DME): A serious eye condition that can lead to vision impairment and blindness, DME is a primary focus of Eyepoint’s efforts in drug development.
- Uveitis: An inflammatory condition affecting the middle layer of the eye, which can result in vision loss if not adequately treated.
Products
1. Yutiq®:
- Overview: Yutiq (fluocinolone acetonide intravitreal implant) is a sustained-release corticosteroid implant approved for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
- Administration: Administered via an in-office procedure, Yutiq provides sustained drug delivery for up to three years, potentially reducing the need for frequent injections and improving patient compliance.
2. DEXYCU®:
- Overview: DEXYCU (dexamethasone intraocular suspension) is a biodegradable drug delivery system designed to treat post-operative inflammation following cataract surgery.
- Benefit: Unlike conventional steroid treatments that require multiple doses, DEXYCU provides a single-dose, sustained-release option that helps manage inflammation effectively and reduces patient burden.
3. Integrated Drug Delivery Systems:
Eyepoint is engaged in developing additional product candidates utilizing its Durasert technology. This encompasses programs aimed at treating various retinal diseases and conditions that require long-term therapy.
Services
1. Clinical Development:
Eyepoint Pharmaceuticals engages in extensive clinical trials to evaluate the safety and efficacy of its product candidates. The company conducts both early-stage and late-stage clinical trials, often working with leading research institutions and ophthalmology experts.
2. Regulatory Support:
The company provides comprehensive support to navigate the complexities of regulatory approvals required for its products. This service involves preclinical assessments, IND applications, and the management of clinical study applications with relevant regulatory bodies.
3. Commercialization Strategies:
Eyepoint focuses on developing strategic partnerships for the commercialization of its products. This includes collaborations with larger pharmaceutical companies that have extensive distribution networks as well as the execution of marketing strategies to increase product awareness and uptake.
4. Educational Programs:
The company also engages in educational initiatives aimed at healthcare professionals and patients. These programs focus on raising awareness about eye diseases, the importance of treatment adherence, and the innovative solutions offered by Eyepoint’s products.
Conclusion
Eyepoint Pharmaceuticals Inc. stands at the forefront of innovation in ocular therapeutics, particularly with its advanced drug delivery technologies and commitment to addressing unmet needs in eye care. With its focus on long-lasting, patient-friendly treatment options, the company seeks to make significant strides in the management of chronic eye diseases, ultimately enhancing the quality of life for those affected.